Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development
AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation.
Ularitide is an advanced natriuretic peptide in Phase III development as an intravenous (IV) infusion treatment for acute heart failure (AHF).
Cardiorentis AG is a privately owned pharmaceutical company based in Zug, Switzerland.
Focused, fast moving, flexible, with patients at its heart, Cardiorentis
is committed to introducing the first therapy with proven outcome
benefits for patients with acute heart failure and developing innovative
medicines for diseases of high unmet medical need.
Cardiorentis is a proud sponsor of the American Heart Association New York City Health Sciences Innovation • Investment Forum
Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure
A review on Ularitide has been published in the highly prestigious Cardiology Journal “European Heart Journal” by world wide known experts in Acute Heart Failure:
At HF 2015 23rd – 26th May in Seville, Spain.
Visit our Stand D10 to find out the latest on the TRUE-AHF trial.